Bio-Gene Technology (ASX:BGT) has commenced a critical acute neurotoxicity study for its flagship nature-derived insecticide, Flavocide.
This marks a milestone in the company's strategic push toward international commercialisation and regulatory approval.
The study, conducted under the rigorous OECD 424 guidelines, is specifically designed to evaluate the impact of Flavocide on the neurological health of mammalian subjects, using Wistar strain Norway rats.
As a core component of the regulatory dossier for the Australian Pesticides and Veterinary Medicines Authority and other global agencies, the study focuses on identifying potential changes in neuro-behaviour and neuropathology.
By establishing a no observed adverse effect level, Bio-Gene aims to validate the safety profile of Flavocide's active constituent.
The company confirmed that the preliminary dose range-finding phase is already complete.
A comprehensive report from the main study is anticipated in May.
The data is essential for characterising the dose-response relationship of the compound, ensuring that the next generation of insecticides meets the highest safety standards for both human health and the environment.